display
Biontech CEO Ugur Sahin has denied criticism of his company for delays in vaccine production.
“As far as production is concerned, we are almost on schedule,” said Sahin in an interview with ARD “Tagesthemen” on Monday evening.
The impression that it is bumpy in the vaccine production is "de facto not right," said Sahin.
The processes that are necessary to ramp up production take time.
Two weeks ago, Biontech announced that it would “temporarily deliver less” in order to expand the production halls and adapt the production processes.
"Now we are able to produce significantly more than we had planned at the end of last year."
display
The vaccination summit today was important, said Sahin, so that everyone “understands the complexity”.
There are no full deposits.
“Everything we produce is delivered immediately.” When asked whether other companies could also produce the Biontech vaccine under license, Sahin said that even large, experienced companies would need “several months” just to set up the bottling plant.
The vaccine from Mainz-based company Biontech and its US partner Pfizer was the first to be approved in the EU on December 21.
In mid-January, companies had to temporarily cut their initial delivery quantities.
The reason was renovation work at the Pfizer plant in Puurs, Belgium.
According to the EU Commission, Biontech and Pfizer are sticking to the total amount promised for the first quarter and want to catch up on the delivery backlog by the end of March.